eViralHepatitis Review
Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study
May 26, 2016
Volume 4, Issue 8, Part 3. Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infecte...
New York
EViralHepatitis Review podcast channel
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast